Gossamer Bio Stock

Gossamer Bio Enterprise Value

The Enterprise Value (EV) of Gossamer Bio (GOSS) as of Aug 3, 2026 is 142.76 M USD. In the previous year, Enterprise Value (EV) was -15.81 M USD — a change of -1,002.75% (higher).

Enterprise Value

142.76 MUSD

YoY

-1,002.75%

Last updated:

Enterprise Value (EV) of Gossamer Bio is 2026 142.76 M USD. Enterprise Value (EV) of Gossamer Bio was 2025 -15.81 M USD. It decreases by -1,002.75% higher compared to the previous year.
Access this data via the Eulerpool API

Gossamer Bio Stock analysis

What does Gossamer Bio do? The company Gossamer Bio Inc. was founded in 2015 by Faheem Hasnain and Sheila Gujrathi. The founders had previously worked at various biotechnology companies and now wanted to start their own company to develop innovative products in the field of immunology. Gossamer Bio is headquartered in San Diego, California and currently employs around 200 people. The company specializes in researching and developing therapeutics for a wide range of diseases, including respiratory diseases, cancer, immunological disorders, and infections. Gossamer Bio's business model is based on identifying promising new drug candidates and subsequently developing therapeutics that have the potential to improve patients' lives. Key pillars of the business model include partnerships with established companies and investors, as well as the rapid and efficient conduct of clinical trials. Gossamer Bio's portfolio includes various pipeline programs in different stages of development. An important focus is on the development of new drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). A promising drug candidate in this area is GB001, an inhalation medication that aims to reduce inflammation in the airways. Another important program of Gossamer Bio is the development of therapeutics for the treatment of cancer. The company focuses on the development of drugs that target the body's immune system to specifically fight tumor cells. A promising drug candidate in this area is GB1275, an antibody that specifically targets a protein overexpressed by some types of cancer. In addition to these two focus areas, Gossamer Bio also has programs in the development of therapeutics for the treatment of immunological disorders such as inflammatory bowel disease and rheumatoid arthritis, as well as for the treatment of infections such as COVID-19. Overall, Gossamer Bio has a wide range of promising drug candidates that have the potential to revolutionize the field of immunology and disease management. The company is well positioned to make significant progress in the development of new therapeutics in the coming years and improve the lives of millions of patients worldwide. Gossamer Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Gossamer Bio stock

Enterprise Value (EV) of Gossamer Bio is 142.76 M USD in 2026.

Enterprise Value (EV) of Gossamer Bio changed from -15.81 M USD to 142.76 M USD, representing a -1,002.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Gossamer Bio since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Gossamer Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Gossamer Bio

All Key Metrics — Gossamer Bio